Ind-Swift Laboratories Ltd

INDSWFTLAB

Watchlist

AI Mode

‌

Market Cap

₹ 795 Cr

P/E

26.83

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

UNDERVALUED

Growth

STABLE

Profitability

LOW MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Ind-Swift Laboratories Limited, based in Chandigarh, India, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) known for its global expertise in Macrolide Antibiotics.

The company recently sold its entire API and CRAMS business to PI Industries in a slump-sale deal effective March 18, 2024, indicating a significant strategic shift.

Despite divesting its API and CRAMS business, Ind-Swift continues its international presence with the recent incorporation of a wholly-owned subsidiary in Dubai, ISLL Middle East L.L.CFZ.

Ind-Swift's history reflects steady capacity expansion and product diversification, having launched a variety of pharmaceuticals like Letrozole and Anastrozole over the years.

Strategic alliances, both through subsidiaries and joint ventures, have been vital for Ind-Swift’s growth, helping leverage market opportunities in different geographies.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

795 Cr

Volatility

Low Risk

P/E Ratio

26.8

Industry P/E

30.8

PEG Ratio

—

P/B Ratio

0.6

52W High

124.45

52W Low

67.15

Sales CAGR

-67.14%

-17.76%

-6.07%

10Y

-1.99%

Profit CAGR

-53.54%

—

10Y

—

ROE

TTM

2.27%

31.38%

21.48%

10Y

11.39%

ROCE

TTM

1.19%

30.86%

20.51%

10Y

12.95%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KPL	943.50	980 Cr	19.97	3.39	0.00	16.91	18.84	10.27
THEMISMED	104.00	965 Cr	—	2.78	0.48	-7.10	-3.47	-4.63
SAKAR	419.75	934 Cr	47.75	3.08	0.00	6.43	8.43	4.35
WANBURY	240.85	836 Cr	19.44	10.80	0.00	51.51	27.98	10.39
ACCENTMIC	342.95	823 Cr	24.89	3.51	0.29	13.89	19.49	12.00
INDSWFTLAB	96.65	795 Cr	26.83	0.61	0.00	2.27	1.19	15.12
KOPRAN	131.70	636 Cr	36.18	1.27	2.28	3.51	5.38	2.17

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	310	290	288	393	33	12	8.66	138	153	153
Expenses	250	224	236	317	43	24	23	147	149	151
Operating Profit	60	66	52	77	-9.74	-12	-15	-9.19	3.60	1.47
OPM %	19.43	22.68	17.98	19.45	-29.36	-98.58	-167.78	-6.65	2.36	0.96
Other Income	5.61	7.40	7.11	412	11	13	14	220	15	18
Interest	20	21	21	-11	0.17	0.41	0.11	-27	1.15	2.01
Depreciation	14	13	14	13	0.25	0.22	0.25	7.44	6.68	6.98
Profit Before Tax	32	39	24	487	0.98	0.58	-1.08	230	10	10
Tax %	45.01	17.87	19.31	27.60	-3.06	31.03	100.00	3.55	16.52	22.24
Net Profit	17	32	20	353	1.01	0.40	-0.01	222	8.65	8.04
EPS in Rs	2.11	3.88	2.38	43.21	0.12	0.05	0.00	22.34	0.87	0.96

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	716	765	757	780	891	1,039	1,207	1,281	562	312
Expenses	610	631	631	635	709	843	978	1,027	581	344
Operating Profit	106	134	126	144	183	196	229	254	-19	-32
OPM %	14.79	17.55	16.66	18.52	20.51	18.83	18.98	19.85	-3.45	-10.24
Other Income	15	16	120	33	23	43	6.85	432	305	262
Interest	88	28	92	107	100	96	92	51	2.92	-25
Depreciation	88	87	104	90	87	131	57	53	24	15
Profit Before Tax	-55	36	50	-20	18	13	87	582	258	240
Tax %	29.24	38.93	41.73	-7.17	117.48	117.15	44.72	27.56	2.82	3.75
Net Profit	-39	22	29	-21	-3.15	-2.15	48	421	251	231
EPS in Rs	—	—	5.21	-3.04	-0.38	-0.27	5.83	51.59	22.51	24.17
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	42	45	46	48	60	60	60	60	59	69
Reserves	476	486	507	540	581	544	541	622	872	1,104
Borrowings	1,250	998	832	1,148	1,031	1,005	953	862	17	41
Other Liabilities	447	608	638	188	198	210	247	280	217	224
Total Liabilities	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,438
Fixed Assets	1,099	1,029	922	901	828	739	628	585	5.36	271
CWIP	78	70	69	20	11	19	10	7.71	0.00	0.00
Investments	18	31	31	31	33	50	32	33	113	216
Other Assets	1,020	1,007	1,002	972	998	1,011	1,131	1,199	1,047	952
Total Assets	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,438

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	79	96	73	-64	125	135	150	195	-163	-25
Cash from Investing Activity	-30	-31	-17	-12	-9.10	-10	4.77	-13	-104	-110
Cash from Financing Activity	-48	-69	-62	100	-133	-124	-141	-186	699	69
Net Cash Flow	1.94	-4.27	-6.30	23	-17	1.03	14	-4.41	431	-66

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Aug 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Jul 2025	Aug 2025	Sep 2025
Promoters	42.00%	42.00%	42.00%	42.00%	42.00%	42.00%	42.00%	40.94%	40.94%	36.77%	37.72%	39.50%
FIIs	0.17%	0.31%	0.25%	1.26%	0.85%	0.65%	0.46%	3.00%	4.27%	16.99%	16.68%	14.80%
DIIs	19.49%	18.73%	8.03%	0.94%	0.94%	0.94%	0.94%	0.91%	0.91%	0.77%	0.75%	0.68%
Public	38.33%	38.95%	49.72%	55.80%	56.21%	56.41%	56.60%	55.14%	53.87%	45.47%	44.84%	45.02%
Total Shareholders	25,405	24,633	22,439	25,461	29,536	28,883	28,752	28,190	28,709	28,907	28,892	43,780

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Aug 28, 2025	Essix biosciences limited	Insider - Promoter	Acquisition	10.00	2.56 Cr	25,55,014	3.47
Aug 28, 2025	S. r. mehta	Insider - Promoter	Acquisition	10.00	0.31 Cr	3,05,380	0.41
Aug 28, 2025	V.r. mehta	Insider - Promoter	Acquisition	10.00	0.29 Cr	2,88,204	0.38
Aug 28, 2025	Sunita jain	Insider - Promoter Group	Acquisition	10.00	0.27 Cr	2,71,860	0.35
Aug 28, 2025	Gopal munjal	Insider - Promoter	Acquisition	10.00	0.29 Cr	2,93,579	0.38
Aug 28, 2025	Neera mehta	Insider - Promoter Group	Acquisition	10.00	0.23 Cr	2,32,057	0.31
Jul 05, 2025	Essix biosciences limited	Insider - Promoter	Acquisition	121.00	13.31 Cr	11,00,000	1.81
May 22, 2025	Pranav joneja	Bulk	Buy	72.73	4.47 Cr	6,14,000	1.01
May 22, 2025	Wilson holdings private limited	Bulk	Sell	72.02	4.39 Cr	6,10,000	1.00
May 16, 2025	Wilson holdings private limited	Bulk	Sell	71.80	2.77 Cr	3,85,685	0.63

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

17 hours ago

Receipt of GMP Certificate from NNGYK-Hungary

Ind-Swift Laboratories Limited has obtained a Good Manufacturing Practice (GMP) certificate from the National Center for Public Health and Pharmacy (NNGYK-Hungary) following a satisfactory EUDRA GMP inspection.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY21

Investor Presentation

Q1 FY21

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	310	290	288	393	33	12	8.66	138	153	153
Expenses	250	224	236	317	43	24	23	147	149	151
Operating Profit	60	66	52	77	-9.74	-12	-15	-9.19	3.60	1.47
OPM %	19.43	22.68	17.98	19.45	-29.36	-98.58	-167.78	-6.65	2.36	0.96
Other Income	5.61	7.40	7.11	412	11	13	14	220	15	18
Interest	20	21	21	-11	0.17	0.41	0.11	-27	1.15	2.01
Depreciation	14	13	14	13	0.25	0.22	0.25	7.44	6.68	6.98
Profit Before Tax	32	39	24	487	0.98	0.58	-1.08	230	10	10
Tax %	45.01	17.87	19.31	27.60	-3.06	31.03	100.00	3.55	16.52	22.24
Net Profit	17	32	20	353	1.01	0.40	-0.01	222	8.65	8.04
EPS in Rs	2.11	3.88	2.38	43.21	0.12	0.05	0.00	22.34	0.87	0.96

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	716	765	757	780	891	1,039	1,207	1,281	562	312
Expenses	610	631	631	635	709	843	978	1,027	581	344
Operating Profit	106	134	126	144	183	196	229	254	-19	-32
OPM %	14.79	17.55	16.66	18.52	20.51	18.83	18.98	19.85	-3.45	-10.24
Other Income	15	16	120	33	23	43	6.85	432	305	262
Interest	88	28	92	107	100	96	92	51	2.92	-25
Depreciation	88	87	104	90	87	131	57	53	24	15
Profit Before Tax	-55	36	50	-20	18	13	87	582	258	240
Tax %	29.24	38.93	41.73	-7.17	117.48	117.15	44.72	27.56	2.82	3.75
Net Profit	-39	22	29	-21	-3.15	-2.15	48	421	251	231
EPS in Rs	—	—	5.21	-3.04	-0.38	-0.27	5.83	51.59	22.51	24.17
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	42	45	46	48	60	60	60	60	59	69
Reserves	476	486	507	540	581	544	541	622	872	1,104
Borrowings	1,250	998	832	1,148	1,031	1,005	953	862	17	41
Other Liabilities	447	608	638	188	198	210	247	280	217	224
Total Liabilities	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,438
Fixed Assets	1,099	1,029	922	901	828	739	628	585	5.36	271
CWIP	78	70	69	20	11	19	10	7.71	0.00	0.00
Investments	18	31	31	31	33	50	32	33	113	216
Other Assets	1,020	1,007	1,002	972	998	1,011	1,131	1,199	1,047	952
Total Assets	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,165	1,438

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	79	96	73	-64	125	135	150	195	-163	-25
Cash from Investing Activity	-30	-31	-17	-12	-9.10	-10	4.77	-13	-104	-110
Cash from Financing Activity	-48	-69	-62	100	-133	-124	-141	-186	699	69
Net Cash Flow	1.94	-4.27	-6.30	23	-17	1.03	14	-4.41	431	-66

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KPL	943.50	980 Cr	19.97	3.39	0.00	16.91	18.84	10.27
THEMISMED	104.00	965 Cr	—	2.78	0.48	-7.10	-3.47	-4.63
SAKAR	419.75	934 Cr	47.75	3.08	0.00	6.43	8.43	4.35
WANBURY	240.85	836 Cr	19.44	10.80	0.00	51.51	27.98	10.39
ACCENTMIC	342.95	823 Cr	24.89	3.51	0.29	13.89	19.49	12.00
INDSWFTLAB	96.65	795 Cr	26.83	0.61	0.00	2.27	1.19	15.12
KOPRAN	131.70	636 Cr	36.18	1.27	2.28	3.51	5.38	2.17

Overview

Detailed Summary

Ind-Swift Laboratories Limited, based in Chandigarh, India, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) known for its global expertise in Macrolide Antibiotics.

The company recently sold its entire API and CRAMS business to PI Industries in a slump-sale deal effective March 18, 2024, indicating a significant strategic shift.

Despite divesting its API and CRAMS business, Ind-Swift continues its international presence with the recent incorporation of a wholly-owned subsidiary in Dubai, ISLL Middle East L.L.CFZ.

Ind-Swift's history reflects steady capacity expansion and product diversification, having launched a variety of pharmaceuticals like Letrozole and Anastrozole over the years.

Strategic alliances, both through subsidiaries and joint ventures, have been vital for Ind-Swift’s growth, helping leverage market opportunities in different geographies.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

795 Cr

Volatility

Low Risk

P/E Ratio

26.8

Industry P/E

30.8

PEG Ratio

—

P/B Ratio

0.6

52W High

124.45

52W Low

67.15

Sales CAGR

-67.14%

-17.76%

-6.07%

10Y

-1.99%

Profit CAGR

-53.54%

—

10Y

—

ROE

TTM

2.27%

31.38%

21.48%

10Y

11.39%

ROCE

TTM

1.19%

30.86%

20.51%

10Y

12.95%